[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657290":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":30,"studyPopulation":18,"armGroups":31,"interventions":43,"overallOfficials":18,"centralContacts":49,"locations":55,"responsibleParty":72,"collaborators":18,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":18,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":18,"enrollmentInfo":83,"targetDuration":18,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":96,"whyStopped":18,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Shenzhen Salubris Pharmaceuticals Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in mean sitting systolic blood pressure (msSBP) at Week 12","msSBP will be measured in the office using a validated sphygmomanometer, with the participant seated and resting quietly for at least 5 minutes. The primary endpoint is the change from baseline, calculated as the Week 12 value minus the baseline value, expressed in mmHg","Baseline and Month 3",[14],{"measure":15,"description":16,"timeFrame":17},"Change from baseline in mean sitting systolic blood pressure (msSBP) at Weeks 4, 8, and 24 of the double-blind period","Change from baseline, calculated as the Week 24 value minus the baseline value, expressed in mmHg","Baseline, Weeks 4, 8, and 24",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":25},"QUADRUPLE",[26,27,28,29],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy, safety, and pharmacokinetics of GW906 Injection used as add-on therapy in patients with hypertension not adequately controlled by one or two antihypertensive medications.\n\nParticipants are randomized to receive either GW906 Injection or placebo for 6 months.",[32,38],{"label":33,"type":34,"description":35,"interventionNames":36},"GW906","ACTIVE_COMPARATOR","Subcutaneous injection. 24 weeks",[37],"Drug: GW906",{"label":39,"type":40,"description":35,"interventionNames":41},"Placebo","PLACEBO_COMPARATOR",[42],"Drug: Placebo",[44,47],{"type":45,"name":33,"description":35,"armGroupLabels":46,"otherNames":18},"DRUG",[33],{"type":45,"name":39,"description":35,"armGroupLabels":48,"otherNames":18},[39],[50],{"name":51,"role":52,"phone":53,"phoneExt":18,"email":54},"Jianan Wang, Professor","CONTACT","86-1599008651","jiguangwang@rjh.com.cn",[56],{"facility":57,"status":18,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"The Second Affiliated Hospital Zhejiang University School of Medicine","Hangzhou","Zhejiang","310009","China","CN",{"type":64,"coordinates":65},"Point",[66,67],120.16142,30.29365,{"lat":67,"lon":66},[70],{"name":51,"role":52,"phone":71,"phoneExt":18,"email":54},"86-15990086511",{"type":73,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100657290","phase-2-a-study-to-evaluate-efficacy-and-safety-of-gw906-used-as-add-on-therapy-in-patients-with-hypertension-not-adequately-controlled-by-one-or-two-antihypertensive-medications-100657290",false,"NCT07835984","A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of GW906 Injection (SAL0132) Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications","Inclusion Criteria:\n\n* Age ≥ 18 years, of either sex.\n* Treated hypertension on stable therapy with up to 1 or 2 antihypertensive medications. Stable therapy is defined as having no change in antihypertensive medication or dose within 4 weeks prior to randomization.\n* Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and \\\u003C 180 mmHg at the randomization visit.\n* Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Secondary hypertension.\n* orthostatic hypotension.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5× upper limit of normal (ULN); Total bilirubin \\> 1.5 × ULN; International normalized ratio (INR) \\> 2.0; Serum potassium \\> 5.0 mmol\u002FL or \\\u003C 3.5 mmol\u002FL; eGFR≤30 mL\u002Fmin\u002F1.73m\\^2.\n* Received an investigational agent within the last 3 months.\n* Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus.\n* History of any cardiovascular event within 12 months.\n* History of intolerance to SC injection(s).","ALL","18 Years",{"count":84,"type":85},560,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906 as add-on therapy.",[91],"Hypertension",[91,93,33,94,95],"siRNA","SAL0132","Add-on Therapy","NOT_YET_RECRUITING","2026-09-17",{"date":99,"type":100},"2026-09-23","ACTUAL",{"date":102,"type":85},"2026-10",{"date":104,"type":85},"2027-10",{"name":5,"class":6},1]